Praxis Medical Insights

Guideline Recommendations

The National Institute for Health and Care Excellence (NICE) guidelines recommend escitalopram and sertraline as first-line pharmacotherapy for social phobia, with fluvoxamine and paroxetine as second-line options due to side effects or discontinuation symptoms, though they are equally effective 1
The German S3 guidelines list escitalopram, paroxetine, and sertraline as standard drugs for pharmacotherapy of social phobia 1
The Canadian Clinical Practice Guidelines list escitalopram, fluvoxamine, paroxetine, and sertraline as first-line SSRIs for social phobia 1
Notably, fluoxetine is not specifically mentioned in any of these guideline hierarchies, despite being an SSRI with demonstrated efficacy 1, 2, 3

Meta-analyses of RCTs showed SSRIs produced significant improvements in treatment response and social anxiety symptoms compared to placebo, with dropout rates similar to placebo 1, 2, 3
The certainty of evidence was downgraded to "low" due to risk of bias, inconsistency, and other methodological concerns 1, 2, 3
The recommendation for SSRIs overall carries a "weak recommendation" grade according to GRADE assessment 1, 2

The American College of Physicians and other guideline societies recommend starting with escitalopram or sertraline as first-line SSRIs based on guideline consensus and favorable side effect profiles 1
If inadequate response after 8-12 weeks at therapeutic doses, switch to another first-line SSRI (paroxetine, fluvoxamine) or consider second-line agents including pregabalin, gabapentin, or benzodiazepines, as recommended by the Canadian Medical Association 4, 5
Monitoring should be performed by a physician with expertise in social anxiety disorder to properly evaluate treatment response 1, 3
Combination therapy with CBT often yields superior results to medication alone, though the large RCT showed no additional benefit of combining fluoxetine with CBT compared to either treatment alone, as noted by the American Psychiatric Association 4